Logo
TheLifesciencesMag Magazine
FDA Approves Durvalumab for Advanced Endometrial Cancer Treatment

On June 14, 2024, the U.S. Food and Drug Administration (FDA) approved AstraZeneca’s drug Durvalumab (IMFINZI®) for the treatment of primary advanced or recurrent endometrial cancer in patients with mismatch repair deficiency.

Endometrial cancer is recognized as the most common gynecologic cancer in the United States, with an estimated 66,200 new cases in 2023 alone.

Know More: https://thelifesciencesmag...

#FDAApproval #Durvalumab #EndometrialCancer #CancerTreatment #DrugApproval #MedicalBreakthrough #oncology
2 months ago

No replys yet!

It seems that this publication does not yet have any comments. In order to respond to this publication from TheLifesciencesMag Magazine, click on at the bottom under it